Oliver Cornely to Voriconazole
This is a "connection" page, showing publications Oliver Cornely has written about Voriconazole.
Connection Strength
0.998
-
COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. Emerg Infect Dis. 2021; 27(4):1077-1086.
Score: 0.192
-
Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019 Feb; 45(1):1-21.
Score: 0.166
-
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses. 2018 Nov; 61(11):868-876.
Score: 0.162
-
Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Antimicrob Agents Chemother. 2018 01; 62(1).
Score: 0.155
-
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018 Feb; 97(2):197-207.
Score: 0.154
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 06; 21(6):e149-e162.
Score: 0.048
-
COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun; 63(6):528-534.
Score: 0.046
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.039
-
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry. Mycoses. 2017 Apr; 60(4):273-279.
Score: 0.036